Christopher Yea - 08 Jul 2025 Form 4 Insider Report for KalVista Pharmaceuticals, Inc. (KALV)

Role
CHIEF DEVELOPMENT OFFICER
Signature
/s/ Benjamin L. Palleiko, Attorney-in-Fact
Issuer symbol
KALV
Transactions as of
08 Jul 2025
Transactions value $
-$474,698
Form type
4
Filing time
10 Jul 2025, 20:50:14 UTC
Previous filing
27 May 2025
Next filing
19 Aug 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Yea Christopher CHIEF DEVELOPMENT OFFICER C/O KALVISTA PHARMACEUTICALS, INC, 55 CAMBRIDGE PARKWAY, SUITE 901E, CAMBRIDGE /s/ Benjamin L. Palleiko, Attorney-in-Fact 10 Jul 2025 0001691102

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction KALV Common Stock Award +60K +61.11% 158K 08 Jul 2025 Direct F1, F2
transaction KALV Common Stock Sale -$475K -30.3K -19.12% $15.69 128K 09 Jul 2025 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Shares earned upon the vesting of a percentage of the performance stock units ("PSUs") granted to the Reporting Person on January 11, 2023. Each PSU represents a contingent right to receive one share of Issuer common stock upon the Issuer's achievement of performance data metric goals ("Performance Metrics"). 100% of the total number of shares subject to the PSUs vested on July 8, 2025, upon Performance Metrics achieved.
F2 Each PSU represents a contingent right to receive 1 share of the Issuer's Common Stock upon settlement for no consideration.
F3 The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of PSUs. The sale was to satisfy tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person.